Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024 PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipantsIMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee H, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Felip E. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2024, 42: lba8035-lba8035. DOI: 10.1200/jco.2024.42.17_suppl.lba8035.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease-free survivalResected non-small cell lung cancerPD-L1Overall survivalPhase III studyITT populationResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerStage II-IIIA non-small cell lung cancerFollow-upDisease-free survival improvementDisease-free survival benefitPD-L1 TCStage II-IIIACell lung cancerIntent-to-treatAdjuvant atezolizumabOS trendIII studiesOS endpointSecondary endpointsAtezoSafety profileLung cancer